Skip to main content

Kobe

 
The Kobe Pharma Research Institute (KPRI).

Boehringer Ingelheim established its research and development presence in Japan in 1969, with the aim of developing and submitting new human pharmaceuticals. Originally, this R&D site was based in Kawanishi, Kansai region. In 2008, it was transferred to its current location in nearby Kobe, where it is known as the Kobe Pharma Research Institute (KPRI). Today, more than 80 employees work in the areas of Discovery Research (RBB), Development (NCE), and Business Development & Licensing.

 
 
Front view of the research building.
 

The KPRI participates in the global R&D activities for human pharmaceuticals, and its main tasks constitute scouting innovations and new technologies in Japan. On top of that, the KPRI supports new drug development and also market submission in order to maximize the value of new products for the Japanese market.

Services

Print this Article

Tags

Sites Around the World